LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

REVOLUTION Medicines Inc

Gesloten

SectorGezondheidszorg

45.22 2.73

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.98

Max

45.33

Belangrijke statistieken

By Trading Economics

Inkomsten

-34M

-248M

EPS

-1.13

Winstmarge

-74.379

Werknemers

700

EBITDA

-24M

-261M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+59.37% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.8B

8.7B

Vorige openingsprijs

42.49

Vorige sluitingsprijs

45.22

Nieuwssentiment

By Acuity

17%

83%

103 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2025, 23:56 UTC

Populaire aandelen

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sep 2025, 22:01 UTC

Belangrijke Marktbewegers

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sep 2025, 20:51 UTC

Acquisities, Fusies, Overnames

UPS Terminates Plan to Buy Estafeta

18 sep 2025, 20:31 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sep 2025, 20:26 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sep 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 sep 2025, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sep 2025, 23:31 UTC

Marktinformatie

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sep 2025, 22:03 UTC

Winsten

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sep 2025, 22:01 UTC

Winsten

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sep 2025, 21:56 UTC

Winsten

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sep 2025, 21:54 UTC

Winsten

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sep 2025, 21:48 UTC

Winsten

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sep 2025, 21:47 UTC

Winsten

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sep 2025, 21:17 UTC

Winsten

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sep 2025, 21:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

United Parcel Service Terminates Plan to Buy Estafeta

18 sep 2025, 20:20 UTC

Acquisities, Fusies, Overnames

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 sep 2025, 20:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:03 UTC

Winsten

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

59.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.24 USD  59.37%

Hoogste 80 USD

Laagste 37.91 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

103 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat